Advertisement
From 2000 to 2015

Total of 0.21 Years Lost Due to Opioid-Related Poisoning Deaths

0
Drug-related poisoning deaths up from 2000 to 2015, with most of the increase due to opioid deaths
A multicomponent intervention is associated with greater reduction in systolic and diastolic blood pressure than usual care over 18 months

Multicomponent Intervention Linked to Greater Drop in BP

0
Intervention beneficial over 18 months for low-income adults in Argentina with uncontrolled HTN
Having no partner is associated with a lower frequency of home blood pressure monitoring

AHA: Home BP Monitoring Down for Those Without Partners

0
Having, being aware of/treated for hypertension linked to increased frequency of home BP monitoring
Some adolescents

AHA: Target Organ Damage From HTN Also Seen in Teenagers

0
Sixteen percent of teenagers had left ventricular hypertrophy with SBP below the 95th percentile
A multifaceted quality improvement program improves blood pressure control over a six-month period

AHA: Multifaceted Intervention Improves BP Control

0
Increase in BP control from 65.6% to 74.8%, with significant increase in control in 12 of 16 practices
For pregnant women with type 1 diabetes

CGM Use in Pregnancy Improves Neonatal Outcomes

0
No apparent benefit for continuous glucose monitoring for women planning pregnancy
For patients after an ischemic stroke or transient ischemic attack

Greater Benefit for Pioglitazone in High-Risk Patients Post Stroke

0
Patients at higher risk for stroke or MI derive greater benefit from pioglitazone versus low-risk patients
Opioid dependence/abuse is a critical public health issue among children in the United States

AAP: Opioid Dependence/Abuse Public Health Issue for Children

0
ER visits for opioid dependence/abuse increased from 32,235 in 2008 to 49,626 in 2013
Spin in biomedical literature (also referred to as "science hype") is prevalent

‘Science Spin’ Found Prevalent in Biomedical Literature

0
Nature of spin varies, with highest variability in prevalence of spin seen in trials
Aliqopa (copanlisib) has been approved by the U.S. Food and Drug Administration to treat adults with relapsed follicular lymphoma who have received at least two prior treatments with certain other drugs.

FDA Approves Aliqopa for Follicular Lymphoma

0
Aliqopa, a kinase inhibitor, blocks several enzymes that promote cell growth